NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Thursday that its fourth quarter revenues sank 24 percent as increases in laboratory services and collaboration revenues were offset by a decrease in product sales.

For the three months ended Dec. 31, the company reported total revenues of $1.0 million, down from $1.3 million in Q4 2015.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.